JP2012505883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505883A5 JP2012505883A5 JP2011532085A JP2011532085A JP2012505883A5 JP 2012505883 A5 JP2012505883 A5 JP 2012505883A5 JP 2011532085 A JP2011532085 A JP 2011532085A JP 2011532085 A JP2011532085 A JP 2011532085A JP 2012505883 A5 JP2012505883 A5 JP 2012505883A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- sv2a inhibitor
- composition
- patent application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 100
- 101710084141 Synaptic vesicle glycoprotein 2A Proteins 0.000 claims description 76
- 239000003112 inhibitor Substances 0.000 claims description 73
- 208000010877 cognitive disease Diseases 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 34
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 28
- 229940102566 valproate Drugs 0.000 claims description 28
- 229960002161 brivaracetam Drugs 0.000 claims description 23
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 claims description 23
- 229960004002 levetiracetam Drugs 0.000 claims description 23
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical group CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims description 23
- 208000028698 Cognitive impairment Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- ANWPENAPCIFDSZ-BQBZGAKWSA-N seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-BQBZGAKWSA-N 0.000 claims description 10
- 229950000852 seletracetam Drugs 0.000 claims description 10
- 230000003920 cognitive function Effects 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 15
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 45
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10584708P | 2008-10-16 | 2008-10-16 | |
| US61/105,847 | 2008-10-16 | ||
| US15263109P | 2009-02-13 | 2009-02-13 | |
| US61/152,631 | 2009-02-13 | ||
| US17553609P | 2009-05-05 | 2009-05-05 | |
| US61/175,536 | 2009-05-05 | ||
| PCT/US2009/005647 WO2010044878A1 (en) | 2008-10-16 | 2009-10-16 | Methods and compositions for improving cognitive function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014129145A Division JP2014169339A (ja) | 2008-10-16 | 2014-06-24 | 認知機能を改善するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505883A JP2012505883A (ja) | 2012-03-08 |
| JP2012505883A5 true JP2012505883A5 (OSRAM) | 2012-11-29 |
| JP5917148B2 JP5917148B2 (ja) | 2016-05-11 |
Family
ID=41403972
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532085A Active JP5917148B2 (ja) | 2008-10-16 | 2009-10-16 | 認知機能を改善するための方法および組成物 |
| JP2014129145A Withdrawn JP2014169339A (ja) | 2008-10-16 | 2014-06-24 | 認知機能を改善するための方法および組成物 |
| JP2016103917A Active JP6271641B2 (ja) | 2008-10-16 | 2016-05-25 | 認知機能を改善するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014129145A Withdrawn JP2014169339A (ja) | 2008-10-16 | 2014-06-24 | 認知機能を改善するための方法および組成物 |
| JP2016103917A Active JP6271641B2 (ja) | 2008-10-16 | 2016-05-25 | 認知機能を改善するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20100099735A1 (OSRAM) |
| EP (2) | EP2346500B1 (OSRAM) |
| JP (3) | JP5917148B2 (OSRAM) |
| CN (2) | CN102227217A (OSRAM) |
| AU (1) | AU2009303834B2 (OSRAM) |
| BR (1) | BRPI0920342A2 (OSRAM) |
| CA (1) | CA2740610C (OSRAM) |
| DK (2) | DK3260118T3 (OSRAM) |
| EA (1) | EA033130B1 (OSRAM) |
| ES (2) | ES2637497T3 (OSRAM) |
| HK (1) | HK1245099A1 (OSRAM) |
| WO (1) | WO2010044878A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010044878A1 (en) | 2008-10-16 | 2010-04-22 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| CN103476255A (zh) * | 2011-02-09 | 2013-12-25 | 约翰斯霍普金斯大学 | 用于改善认知功能的方法和组合物 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| ES2881081T3 (es) | 2013-03-15 | 2021-11-26 | Agenebio Inc | Procedimientos y composiciones para mejorar la función cognitiva |
| US20160030391A1 (en) * | 2013-03-15 | 2016-02-04 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EP2968237A4 (en) * | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| ES2747993T3 (es) * | 2015-05-22 | 2020-03-12 | Agenebio Inc | Composiciones farmacéuticas de liberación prolongada de levetiracetam |
| AU2016381366A1 (en) | 2015-12-30 | 2018-06-28 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
| PL3458049T3 (pl) * | 2016-05-20 | 2025-06-23 | Institut Pasteur | Lewetyracetam, briwaracetam lub selectracetam do zastosowania w leczeniu ostrej dysfunkcji mózgowia wywołanej sepsą |
| US10370561B2 (en) | 2016-06-28 | 2019-08-06 | Prc-Desoto International, Inc. | Urethane/urea-containing bis(alkenyl) ethers, prepolymers prepared using urethane/urea-containing bis(alkenyl) ethers, and uses thereof |
| US11098222B2 (en) | 2018-07-03 | 2021-08-24 | Prc-Desoto International, Inc. | Sprayable polythioether coatings and sealants |
| CN109892247B (zh) * | 2019-04-19 | 2023-08-18 | 桂林医学院 | 一种猫参与的检测大鼠认知功能的实验装置 |
| CN112569216B (zh) * | 2019-09-30 | 2022-02-15 | 厦门大学 | 戊酸衍生物在治疗唐氏综合征中的应用 |
| MX2023000405A (es) * | 2020-07-10 | 2023-05-10 | Agenebio Inc | Combinaciones de agonistas del receptor a del acido gamma aminobutirico (gabaa) alfa 5 e inhibidores de la glicoproteina de vesicula sinaptica 2a (sv2a) y metodos de uso en el tratamiento del deterioro cognitivo. |
| EP4438119A3 (en) * | 2021-02-26 | 2024-11-27 | Syndesi Therapeutics SA | Compound for treatment of cognitive disorders |
| US20240132513A1 (en) | 2022-08-19 | 2024-04-25 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1309692A (en) | 1970-02-13 | 1973-03-14 | Ucb Sa | N-substituted lactams |
| GB1039113A (en) | 1964-08-06 | 1966-08-17 | Ucb Sa | New n-substituted lactams |
| IT1045043B (it) * | 1975-08-13 | 1980-04-21 | Isf Spa | Derivati pirrolidinici |
| IT1075280B (it) * | 1977-02-11 | 1985-04-22 | Isf Spa | Procedimento per la preparazione di derivati pirrolidinici |
| BE864269A (fr) * | 1977-03-03 | 1978-06-16 | Parke Davis & Co | Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire |
| DE2960194D1 (en) * | 1978-05-08 | 1981-04-16 | Ucb Sa | Lactam-n-acetic acids, their amides, process for their preparation and therapeutic compositions containing them |
| US4654370A (en) * | 1979-03-12 | 1987-03-31 | Abbott Laboratories | Glyceryl valproates |
| US4372960A (en) * | 1980-12-12 | 1983-02-08 | Warner-Lambert Company | Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators |
| FR2515179A1 (fr) * | 1981-07-24 | 1983-04-29 | Hoffmann La Roche | Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique |
| IL67623A (en) * | 1983-01-05 | 1984-09-30 | Teva Pharma | 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it |
| IL72381A (en) | 1983-07-20 | 1988-03-31 | Sanofi Sa | Pharmaceutical composition based on valproic acid |
| US4558070A (en) * | 1983-10-26 | 1985-12-10 | Abbott Laboratories | Acid salts of valproic acid |
| GB8412357D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| GB8412358D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| US4668687A (en) * | 1984-07-23 | 1987-05-26 | Bristol-Myers Company | Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones |
| US4913906B1 (en) | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
| JPS6222785A (ja) * | 1985-07-23 | 1987-01-30 | Sanwa Kagaku Kenkyusho:Kk | 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤 |
| IT1190133B (it) * | 1986-06-19 | 1988-02-10 | Chiesi Farma Spa | Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| DE3709230A1 (de) | 1987-03-20 | 1988-10-06 | Desitin Arzneimittel Gmbh | Neues calciumsalz der valproinsaeure |
| JPS6422883A (en) * | 1987-07-17 | 1989-01-25 | Sanwa Kagaku Kenkyusho Co | 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient |
| ES2026198T3 (es) | 1987-07-22 | 1992-04-16 | Farvalsa Ag | Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion. |
| NZ232112A (en) | 1989-01-17 | 1992-07-28 | Hoffmann La Roche | ((5-oxo-2-pyrrolidinyl)methyl)cyclohexaneacetamides, intermediates therefor and pharmaceutical compositions |
| FR2643556B1 (fr) | 1989-02-27 | 1993-03-05 | Sanofi Sa | Composition pharmaceutique a liberation prolongee d'acide valproique |
| IT1231477B (it) * | 1989-07-12 | 1991-12-07 | Sigma Tau Ind Farmaceuti | (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
| CZ281170B6 (cs) * | 1991-05-02 | 1996-07-17 | Daiichi Pharmaceutical Co., Ltd | Léčivo pro léčení demence |
| US5439930A (en) * | 1992-04-14 | 1995-08-08 | Russian-American Institute For New Drug Development | Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects |
| US5440023A (en) | 1992-09-18 | 1995-08-08 | Beckman Instruments, Inc. | Method for making valproic acid derivatives |
| GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| US5468733A (en) | 1993-09-30 | 1995-11-21 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5516759A (en) | 1994-12-08 | 1996-05-14 | Tap Holdings Inc. | LHRH antagonists having lactam groups at the N-terminus |
| IT1285801B1 (it) | 1996-10-10 | 1998-06-24 | Sigma Tau Ind Farmaceuti | Procedimento migliorato per la preparazione dell'acido valproico |
| US6131106A (en) * | 1998-01-30 | 2000-10-10 | Sun Microsystems Inc | System and method for floating-point computation for numbers in delimited floating point representation |
| US6620802B1 (en) * | 1999-11-23 | 2003-09-16 | Corcept Therapeutics, Inc. | Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist |
| JP4249415B2 (ja) | 1999-12-01 | 2009-04-02 | ユセベ，ソシエテ アノニム | Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物 |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| MXPA03005889A (es) * | 2000-12-28 | 2005-02-14 | Daiichi Seiyaku Co | Agente para tratamiento terapeutico y profilactico del dolor neuropatico. |
| US6610326B2 (en) | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
| AU2002245486B2 (en) * | 2001-02-23 | 2006-11-16 | Ucb Pharma, S.A. | Treatment of tics, tremors and related disorders |
| WO2002094787A1 (en) | 2001-05-23 | 2002-11-28 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| WO2003018005A1 (en) * | 2001-08-22 | 2003-03-06 | Daiichi Pharmaceutical Co., Ltd. | use of nefiracetam for treating neurodegeneration |
| JP4484515B2 (ja) | 2001-10-16 | 2010-06-16 | メモリ ファーマセチカル コーポレーション | 神経病症候群の治療の為のｐｄｅ−４阻害剤としての、４−（４−アルコキシ−３−ヒドロキシフェニル）−２−ピロリディン誘導体。 |
| US20040116506A1 (en) * | 2002-06-20 | 2004-06-17 | Krusz John Claude | Use of levetiracetam for treating or preventing acute headaches |
| US7557137B2 (en) * | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
| US7090985B2 (en) * | 2002-12-03 | 2006-08-15 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| JP2006516390A (ja) * | 2002-12-03 | 2006-07-06 | ユ セ ベ ソシエテ アノニム | 発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法 |
| ITMI20030573A1 (it) * | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
| TW200508197A (en) | 2003-03-31 | 2005-03-01 | Ucb Sa | Indolone-acetamide derivatives, processes for preparing them and their uses |
| ATE424384T1 (de) * | 2003-12-02 | 2009-03-15 | Ucb Pharma Sa | Imidazolderivate, verfahren zu deren herstellung und deren anwendungen |
| EP1740575A2 (en) | 2004-04-22 | 2007-01-10 | Eli Lilly And Company | Pyrrolidine derivatives useful as bace inhibitors |
| MXPA06014201A (es) | 2004-06-11 | 2007-03-12 | Ucb Sa | Proceso para preparar derivados de 2-oxo-1-pirrolidina. |
| US20060063707A1 (en) * | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| MX2007009088A (es) * | 2005-01-27 | 2007-09-13 | Alembic Ltd | Formulacion de liberacion extendida de levetiracetam. |
| US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
| WO2006102750A1 (en) * | 2005-03-30 | 2006-10-05 | Genpharm Inc. | Combined-step process for pharmaceutical compositions |
| WO2006128693A2 (en) | 2005-06-01 | 2006-12-07 | Ucb Pharma, S.A. | 2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system |
| EP1731149A1 (en) * | 2005-06-08 | 2006-12-13 | Ucb S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy |
| GB0517740D0 (en) | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| CA2631885A1 (en) | 2005-12-07 | 2007-06-14 | Ucb Pharma, S.A. | Xanthine derivatives, processes for preparing them and their uses |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP1991212A1 (en) | 2006-03-08 | 2008-11-19 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| EP2026813A2 (en) * | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| US20080014264A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
| EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| WO2008095221A1 (en) * | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| EP2152262A2 (en) | 2007-04-27 | 2010-02-17 | UCB Pharma, S.A. | New heterocyclic derivatives useful for the treatment of cns disorders |
| KR20090031333A (ko) | 2007-09-21 | 2009-03-25 | 주식회사 엘지생명과학 | 신규한 베타-세크리타제 저해용 화합물 |
| US20090176740A1 (en) | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
| AU2009221177B2 (en) * | 2008-03-03 | 2013-05-30 | Ucb Biopharma Sprl | Pharmaceutical solutions, process of preparation and therapeutic uses |
| JP2010024156A (ja) | 2008-07-16 | 2010-02-04 | Ucb Pharma Sa | レベチラセタムを含む医薬組成物 |
| WO2010015029A1 (en) | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating psychiatric disorders |
| WO2010044878A1 (en) | 2008-10-16 | 2010-04-22 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| US9125898B2 (en) * | 2008-11-14 | 2015-09-08 | Neurotune Ag | Acetam derivatives for pain relief |
| EP2358360B1 (en) | 2008-11-18 | 2016-09-14 | UCB Biopharma SPRL | Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative |
| DK2391351T3 (da) | 2009-01-29 | 2014-12-01 | Ucb Pharma Sa | Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater |
| WO2010089372A1 (en) | 2009-02-09 | 2010-08-12 | Ucb Pharma, S.A. | Pharmaceutical compositions comprising brivaracetam |
| WO2011015349A2 (en) | 2009-08-07 | 2011-02-10 | Ucb Pharma, S.A. | Methods for enhancing the cognitive function |
| CA2986598C (en) * | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
-
2009
- 2009-10-16 WO PCT/US2009/005647 patent/WO2010044878A1/en not_active Ceased
- 2009-10-16 CN CN2009801474233A patent/CN102227217A/zh active Pending
- 2009-10-16 AU AU2009303834A patent/AU2009303834B2/en active Active
- 2009-10-16 EP EP09748527.0A patent/EP2346500B1/en active Active
- 2009-10-16 ES ES09748527.0T patent/ES2637497T3/es active Active
- 2009-10-16 ES ES17167125T patent/ES2865504T3/es active Active
- 2009-10-16 DK DK17167125.8T patent/DK3260118T3/da active
- 2009-10-16 CN CN201710440380.4A patent/CN107243007A/zh active Pending
- 2009-10-16 EP EP17167125.8A patent/EP3260118B1/en active Active
- 2009-10-16 EA EA201170571A patent/EA033130B1/ru not_active IP Right Cessation
- 2009-10-16 BR BRPI0920342-7A patent/BRPI0920342A2/pt active IP Right Grant
- 2009-10-16 CA CA2740610A patent/CA2740610C/en active Active
- 2009-10-16 US US12/580,464 patent/US20100099735A1/en not_active Abandoned
- 2009-10-16 DK DK09748527.0T patent/DK2346500T3/en active
- 2009-10-16 JP JP2011532085A patent/JP5917148B2/ja active Active
-
2011
- 2011-11-02 US US13/287,531 patent/US8604075B2/en active Active
-
2014
- 2014-04-25 US US14/261,962 patent/US20150094352A1/en not_active Abandoned
- 2014-06-24 JP JP2014129145A patent/JP2014169339A/ja not_active Withdrawn
-
2016
- 2016-05-25 JP JP2016103917A patent/JP6271641B2/ja active Active
-
2018
- 2018-04-06 HK HK18104537.2A patent/HK1245099A1/zh unknown
-
2021
- 2021-08-17 US US17/404,124 patent/US20220218665A1/en not_active Abandoned
-
2023
- 2023-10-03 US US18/376,127 patent/US20240293363A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505883A5 (OSRAM) | ||
| WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
| JP2007507538A5 (OSRAM) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| WO2008027557A3 (en) | Topiramate compositions and methods of enhancing its bioavailability | |
| WO2008064192A3 (en) | Modified release analgesic suspensions | |
| JP2019517542A5 (OSRAM) | ||
| JP2010525050A5 (OSRAM) | ||
| KR102059027B1 (ko) | Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물 | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| JP2015524444A5 (OSRAM) | ||
| JP2015522630A5 (OSRAM) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| CN1856339A (zh) | 肺动脉高血压症治疗的伊洛前列素联合疗法 | |
| KR20090115863A (ko) | 부프레노르핀 및 날록손을 함유하는 개량된 약용 조성물 | |
| WO2011028794A2 (en) | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist | |
| JP2012502047A5 (OSRAM) | ||
| NO20080244L (no) | Doseringsstyring for prasugrel | |
| CL2024003616A1 (es) | Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2016505050A5 (OSRAM) | ||
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| JP2022553175A (ja) | がんの処置における使用のためのα－メチル－ＤＬ－チロシンのアルキルエステル | |
| KR20240069750A (ko) | 신경 장애의 치료 | |
| AU2008253776A8 (en) | Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence | |
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия |